- Home
- TERN vs ARCT Comparison
TERN vs ARCT Comparison
Compare TERN & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- ARCT
- Stock Information
- Founded
- TERN 2017
- ARCT 2013
- Country
- TERN United States
- ARCT United States
- Employees
- TERN N/A
- ARCT N/A
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- TERN Health Care
- ARCT Health Care
- Exchange
- TERN Nasdaq
- ARCT Nasdaq
- Market Cap
- TERN 349.4M
- ARCT 373.7M
- IPO Year
- TERN 2021
- ARCT N/A
- Fundamental
- Price
- TERN $6.09
- ARCT $15.45
- Analyst Decision
- TERN Buy
- ARCT Strong Buy
- Analyst Count
- TERN 5
- ARCT 8
- Target Price
- TERN $15.63
- ARCT $52.83
- AVG Volume (30 Days)
- TERN 962.3K
- ARCT 444.7K
- Earning Date
- TERN 08-04-2025
- ARCT 08-04-2025
- Dividend Yield
- TERN N/A
- ARCT N/A
- EPS Growth
- TERN N/A
- ARCT N/A
- EPS
- TERN N/A
- ARCT N/A
- Revenue
- TERN N/A
- ARCT $143,680,000.00
- Revenue This Year
- TERN N/A
- ARCT N/A
- Revenue Next Year
- TERN N/A
- ARCT $34.08
- P/E Ratio
- TERN N/A
- ARCT N/A
- Revenue Growth
- TERN N/A
- ARCT 15.38
- 52 Week Low
- TERN $1.87
- ARCT $8.04
- 52 Week High
- TERN $11.40
- ARCT $25.88
- Technical
- Relative Strength Index (RSI)
- TERN 81.45
- ARCT 65.55
- Support Level
- TERN $5.54
- ARCT $12.75
- Resistance Level
- TERN $5.75
- ARCT $15.20
- Average True Range (ATR)
- TERN 0.30
- ARCT 0.84
- MACD
- TERN 0.12
- ARCT 0.10
- Stochastic Oscillator
- TERN 95.96
- ARCT 87.66
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.